Generic erosion will see atrial fibrillation market decline

As patents expire and low-cost generics enter the sector, the atrial fibrillation (AF) market is forecast to decline at a compound annual growth rate (CAGR) of 1.3% from $14.53 billion in 2022 to $12.8 billion in 2032 across the eight major markets (8MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), Canada, and Japan).

Data and analytics company GlobalData’s healthcare analyst Amy Murray noted that patent expiration and subsequent generic erosion of the novel oral anticoagulants (NOACs) will have a significant effect on the AF market, especially as this drug class is the current standard of care for stroke prevention in AF.

Late-stage pipeline candidates